Related Experiment Video
Updated: Mar 5, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil
Maurizio Ghisoli1, McCarley Rutledge, Philip J Stephens
1*Mary Crowley Cancer Research Centers †Texas Oncology, P.A. ‡Medical City Dallas Hospital ∥ProPath ¶Gradalis Inc. #Strike Bio, Dallas, TX §Foundation Medicine, Cambridge, MA.
Ewing sarcoma is a rare cancer. A patient with recurrent metastatic Ewing sarcoma achieved a sustained complete response using Vigil (GMCSF/bi-shRNA furin DNA autologous tumor immunotherapy), suggesting its potential efficacy.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Research
Background:
- Ewing sarcoma presents a significant therapeutic challenge, characterized by high resistance to conventional treatments.
- Survival rates for patients experiencing treatment failure, particularly with metastatic recurrence, remain critically low (<10% at 5 years).
Observation:
- A case report details an Ewing sarcoma patient with metastatic disease recurrence less than two years post-standard chemotherapy and radiation.
- The patient received two treatment series of Vigil (GMCSF/bi-shRNA furin DNA autologous tumor immunotherapy), manufactured from tumor recurrences.
Findings:
- The patient achieved a durable and sustained complete response following Vigil treatment.
- Correlation with the ELISPOT assay was observed, indicating an immune response.
Implications:
- These findings support further investigation into Vigil as a potential treatment for recurrent Ewing sarcoma.
- The ELISPOT assay may serve as a valuable biomarker for assessing immune response and correlating it with disease control in patients receiving immunotherapy.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Related Concept Videos
Tumor Immunotherapy
Treatment Resistant Cancers
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...